{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:14:14Z","timestamp":1787004854950,"version":"build-2736575974"},"reference-count":25,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1055\/a-1496-5414","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T18:30:37Z","timestamp":1652293837000},"page":"626-636","source":"Crossref","is-referenced-by-count":1,"title":["Neue Entwicklungen in der Therapie des Diabetes mellitus Typ 2"],"prefix":"10.1055","volume":"147","author":[{"given":"Sophie Charlotte","family":"Hintze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Terkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"ref1","volume-title":"International Diabetes Federation IDF Diabetes Atlas","year":"2019","edition":"9. Aufl."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.2337\/dc-17-0954","article-title":"Burden of Mortality Attributable to Diagnosed Diabetes: A Nationwide Analysis Based on Claims Data From 65 Million People in Germany","volume":"40","author":"E Jacobs","year":"2017","journal-title":"Diabetes Care"},{"key":"ref3","volume-title":"Deutscher Gesundheitsbericht Diabetes","author":"Deutsche Diabetes Gesellschaft (DDG)","year":"2021"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.2337\/diacare.27.8.1879","article-title":"The incidence of congestive heart failure in type 2 diabetes: an update","volume":"27","author":"G A Nichols","year":"2004","journal-title":"Diabetes Care"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/ NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"A S Go","year":"2004","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/ NEJMc1902837","article-title":"Dapagliflozin and Cardiovascular outcomes in Type 2 Diabetes","volume":"380","author":"S Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"C Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"ref9","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"C P Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/ NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"J JV McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/ NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"M Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"S D Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/ NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"H J Heerspink","year":"2019","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/ NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"S P Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/ S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"G C Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/ NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"S P Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"04","key":"ref17","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"R E Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab905","article-title":"An indirect treatment comparison of semaglutide 2.0 mg versus dulaglutide 3.0 mg and 4.5 mg using multi-level network meta-regression","author":"I Lingvay","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"01","key":"ref20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13098-021-00713-9","article-title":"Advances in GLP-1 treatment: focus on oral semaglutide","volume":"13","author":"F G Eliaschewitz","year":"2021","journal-title":"Diabetol Metab Syndr"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly Semaglutide in adults with oberweight or obesity","volume":"384","author":"J PH Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"06","key":"ref22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"P J Frias","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"07","key":"ref23","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2337\/dc20-2878","article-title":"A randomized, open-label Comparison of once-weekly Insulin Icodec Titration Strategies versus once-daily Insulin glargine U100","volume":"44","author":"I Lingvay","year":"2021","journal-title":"Diabetes Care"},{"issue":"23","key":"ref24","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/ NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"G L Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"B Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"09","key":"ref26","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00108-019-0649-9","article-title":"Incretin-based co- and tri-agonists: Innovative pholypharmacology for the treatment of obesity and diabetes","volume":"60","author":"A Harger","year":"2019","journal-title":"Internist (Berl)"},{"issue":"S 02","key":"ref28","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1055\/a-1394-2313","article-title":"Therapie des Typ-2-Diabetes","volume":"16","author":"R Landgraf","year":"2021","journal-title":"Diabetologie und Stoffwechsel"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1496-5414.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T18:32:29Z","timestamp":1652293949000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1496-5414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,5,11]]},"published-print":{"date-parts":[[2022,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1496-5414","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}